An open-label, phase 1a/b study of AB248, a CD8+selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab in patients with advanced solid tumors

被引：0
|
作者：
Buchbinder, Elizabeth I.
Spigel, David R.
Albany, Costantine
Chisamore, Michael
Moynihan, Kelly D.
Liu, Xiaohan
DelNagro, Christopher
Axt, Matt
Pirzkall, Andrea
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT250
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT250
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial
    Friedlander, Michael
    Meniawy, Tarek
    Markman, Ben
    Mileshkin, Linda
    Harnett, Paul
    Millward, Michael
    Lundy, Joanne
    Freimund, Alison
    Norris, Christie
    Mu, Song
    Wu, John
    Paton, Virginia
    Gao, Bo
    LANCET ONCOLOGY, 2019, 20 (09): : 1306 - 1315
  • [32] A FIRST-IN-HUMAN, MULTICENTER, PHASE 1/2, OPEN-LABEL STUDY OF XTX101 IN PATIENTS WITH ADVANCED SOLID TUMORS
    Powderly, John
    Norman, Teleen
    Duncan, Meghan
    Huber, Martin
    O'Neil, Jennifer
    Patel, Ekta
    Vandross, Andrae
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A549 - A549
  • [33] A First in Human (FIH), Phase 1 Open Label, Dose Escalation and Expansion Study of CTM103, a LNP MRNA Encoding an IL2Rß? Selective Il-2v, As Monotherapy and in Combination with Pembrolizumab, in Patients with Advanced Solid Tumors
    Kong, C.
    Zhang, J.
    Sun, L.
    Xuan, Q.
    Huang, H.
    Wang, K.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S122 - S123
  • [34] A PHASE 1A/1B DOSE-ESCALATION STUDY OF INTRAVENOUSLY ADMINISTERED SB 11285 ALONE AND IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
    Abbas, A.
    Strauss, J.
    Janku, F.
    Karim, R.
    Olszanski, A.
    Luke, J. J.
    Leach, K.
    Iyer, R.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A7 - A8
  • [35] INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors
    John F. Hilton
    Patrick A. Ott
    Aaron R. Hansen
    Zujun Li
    Matthen Mathew
    Cristina H. Messina
    Vimal Dave
    Xiao Ji
    Natalie O. Karpinich
    Steven Hirschfeld
    Marc Ballas
    Dan P. Zandberg
    Cancer Immunology, Immunotherapy, 73
  • [36] ALKS 4230, an engineered IL-2 fusion protein, in monotherapy dose-escalation and combination therapy with pembrolizumab in patients with solid tumors: ARTISTRY-1 trial
    Vaishampayan, Ulka
    Muzaffar, Jameel
    Velcheti, Vamsidhar
    Hoimes, Christopher
    Gilbert, Lucy
    McDermott, David
    Spreafico, Anna
    Chu, Quincy
    Curtis, Kelly
    Du, Yangchun
    Mackenzie, Harald
    Sun, Lei
    Putiri, Emily
    Losey, Heather
    Dezube, Bruce
    Ernstoff, Marc
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [37] INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors
    Hilton, John F.
    Ott, Patrick A.
    Hansen, Aaron R.
    Li, Zujun
    Mathew, Matthen
    Messina, Cristina H.
    Dave, Vimal
    Ji, Xiao
    Karpinich, Natalie O.
    Hirschfeld, Steven
    Ballas, Marc
    Zandberg, Dan P.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (03)
  • [38] CAIRE: A basket multicenter open-label phase 2 study evaluating the EZH2 inhibitor tazemetostat in combination with durvalumab in patients with advanced solid tumors
    Italiano, Antoine
    Isambert, Nicolas
    Metges, Jean-Philippe
    Toulmonde, Maud
    Cousin, Sophie
    Pernot, Simon
    Spalato, Mariella
    Grellety, Thomas
    Auzanneau, Celine
    Lortal, Barbara
    Kind, Michele
    Le Loarer, Francoid
    Sellan-Albert, Sabrina
    Bellera, Carine A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] DELTA-2: A PHASE 1, OPEN-LABEL, MULTICENTER STUDY OF ITIL-168, AN AUTOLOGOUS TUMORINFILTRATING LYMPHOCYTE (TIL) CELL THERAPY, WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
    Yeku, Oladapo
    Olson, Daniel
    Ward, Jeffrey
    Patel, Sandip
    Aycock, Jeff
    Donahue, Amber
    Jiang, Yizhou
    Le Gall, John
    Roberts, Zachary
    Alvarez-Rodriguez, Ruben
    Seng, Judy
    Shen, Tong
    Kothari, Nishi
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A813 - A813
  • [40] Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study (vol 8, e000437, 2020)
    Shen, L.
    Guo, J.
    Zhang, Q.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
12345